X

G.R. Health Aids Private Limited

Gujranwala Town, New Delhi, Delhi

| GST  07AABCG0933G1ZZ

is a member of IndiaMART

| Verified Supplier

|

View Mobile Number 78% Response Rate

Hemophilia

Thanks in part to hemophilia therapies currently available, life expectancy for hemophilia patients has increased on average to more than 60 years today.2 Baxter is committed to actively listening to and working with the hemophilia community to proactively shape the future of hemophilia by focusing on personalized innovations and solutions.

Baxter's range of hemophilia therapies allows clinicians to choose the appropriate therapy based on individual patient needs.

Antihemophilic Factor
Interested in this product?
Get Best Quote

Antihemophilic Factor

Rs 3,500 / PieceGet Latest Price

Hemofil m - antihemophilic factor (human) method m, monoclonal purified
the information contained in this page is intended for indian healthcare professionals only.

hemofil m is the first monoclonal antibody purified, solvent detergent–treated factor viii therapy. 1 prepared exclusively with source plasma from baxter's qualified donor program, hemofil m has over 20 years of post-licensure clinical experience. 1,2


indications :


hemofil m is indicated in hemophilia a (classical hemophilia) for the prevention and control of hemorrhagic episodes. Hemofil m is not indicated for von willebrand's disease.


features :


  • use of pooled human plasma
  • patented method m purification process
  • available in 250 iu dosage strengths
  • to be stored at [2° - 8°c (36° - 46°f)] or at room temperature, not to exceed 30°c (86°f), until expiration date noted on the package. Avoid freezing to prevent damage to the diluent bottle.
  • 10 ml diluent vial


safety and efficacy :


efficacious for the control and prevention of bleeding episodes in hemophilia a. 3


important risk information for hemofil m therapy


  • hemofil m is contraindicated in patients with known hypersensitivity to mouse proteins.
  • hemofil m is made from human plasma. It may carry a risk of transmitting infectious agents, e. G. , viruses and theoretically, the creutzfeldt-jakob disease (cjd) agent.
  • certain components used in the packaging of hemofil m contain natural rubber latex.
  • identification of the clotting defect as a factor viii deficiency is essential before the administration of hemofil m is initiated.
  • the development of inhibitors to factor viii is a known complication of the treatment of patients with hemophilia a. If expected plasma fviii levels are not attained, or bleeding is not controlled with an appropriate dose, test for the presence of inhibitors.
  • hemofil m contains trace amounts of mouse protein, and the possibility exists that patients may develop hypersensitivity. Symptoms include hives, generalized urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis. Advise patients to discontinue use of the product and contact a physician if these symptoms occur.
  • the pulse rate should be determined before and during administration of hemofil m. Should a significant increase in pulse rate occur, reducing the rate of administration or temporarily halting the injection usually allows the symptoms to disappear promptly.
  • the protein in greatest concentration in hemofil m is albumin (human). Reactions associated with albumin are extremely rare, although nausea, fever, chills, and urticaria have been reported.

View Complete Details

Yes, I am interested!

Recombinate - Antihemophilic Factor (Recombinant)
Interested in this product?
Get Best Quote
The information contained in this page is intended for Indian healthcare professionals only.

RECOMBINATE was the first genetically engineered, non-plasma-derived factor VIII therapy in the world.1 RECOMBINATE has over 18 years of post-licensure clinical experience.2,3 To date, no confirmed spontaneous reports of hepatitis A, B, C, or HIV transmission or CJV have been received that can be definitively linked to RECOMBINATE administration.4


Indications :


RECOMBINATE is indicated in hemophilia A (classical hemophilia) for the prevention and control of hemorrhagic episodes and for the perioperative management of patients with hemophilia A.4 RECOMBINATE is not indicated for von Willebrand's disease.


Features :

  • Full-length recombinant factor VIII molecule
  • Available in three single vial dosage strengths – 250 IU, 500 IU, 1000 IU
  • Store in a refrigerator (2°C – 8°C). Do not freeze.
  • Within its shelf-life, the product may be stored at 15°C - 25°C prior to use for up to six months.
  • 10 mL diluent vial
  • Packaged with BAXJECT II Needle-less Transfer Device


Safety and Efficacy :



Efficacious for the control and prevention of bleeding episodes in both adults and children with hemophilia A


Important Risk Information for RECOMBINATE Therapy

  • RECOMBINATE may be contraindicated in patients with known hypersensitivity to active substance, excipients or mouse, hamster, or bovine proteins.
  • The development of inhibitors to Factor VIII is a known complication of the treatment of patients with hemophilia A. Inhibitors have predominantly been reported in previously untreated patients. If expected plasma FVIII levels are not attained, or bleeding is not controlled with an appropriate dose, test for the presence of inhibitors.
  • Allergic type hypersensitivity reactions, including anaphylaxis, have been observed with RECOMBINATE and include hives, generalized urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis. Patients should be advised to discontinue use of the product and contact their physician if these symptoms occur.
  • During controlled clinical studies with RECOMBINATE the most commonly reported adverse drug reactions were chills, flushing, rash, and epistaxis.
  • Post marketing adverse reactions have been reported and include the following: Factor VIII inhibition, vomiting, malaise, injection site reactions, anaphylactic reaction, hypersensitivity, loss of consciousness, headache, paresthesia, dyspnea, cough, angioedema, urticaria, and erythema.

View Complete Details

Yes, I am interested!

Immunate
Interested in this product?
Get Best Quote

Immunate

Rs 3,700 / PieceGet Latest Price

The information contained in this page is intended for Indian healthcare professionals only.


Therapeutic indications :


Immunate is a highly purified, double virus inactivated, plasma derived Factor VIII/von Willebrand Factor (VWF) complex concentrate, suitable for the treatment of haemophilia A and von Willebrand Disease with FVIII deficiency.


Features :


  • Use of pooled human plasma
  • Available in 250 IU dosage strength-
  • Active substance - Factor VIII – 50IU/ml and vWF -25IU/ml
  • To be stored at [2° - 8°C (36° - 46°F)] or at room temperature, not to exceed 25°C for a period of 6 months
  • 5 mL diluent vial

Safety and Efficacy :


Efficacious for the control and prevention of bleeding episodes in hemophilia A and Von Willebrand disease.


Important Risk Information for IMMUNATE Therapy

IMMUNATE is made from human plasma. It may carry a risk of transmitting infectious agents, e.g., viruses and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. Certain components used in the packaging of IMMUNATE contain natural rubber latex. Identification of the clotting defect as a Factor VIII deficiency is essential before the administration of IMMUNATE is initiated. The development of inhibitors to Factor VIII is a known complication of the treatment of patients with Hemophilia A. If expected plasma FVIII levels are not attained, or bleeding is not controlled with an appropriate dose, test for the presence of inhibitors. IMMUNATE contains traces of human proteins other than FVIII and the possibility exists that patients may develop hypersensitivity. Symptoms include hives, generalized urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis. Advise patients to discontinue use of the product and contact a physician if these symptoms occur.

The pulse rate should be determined before and during administration of IMMUNATE Should a significant increase in pulse rate occur, reducing the rate of administration or temporarily halting the injection usually allows the symptoms to disappear promptly.

View Complete Details

Yes, I am interested!
4.5/5★★★★★★★★★★

Reviewed by 13 Users

5 star10

4 star1

3 star1

2 star0

1 star1

User Satisfaction

Response100%

Quality100%

Most Relevant Reviews

K

Ketan Bhandari ★★★★★ ★★★★★

18-November-20

R

Rohit Mishra ★★★★★ ★★★★★

17-July-20

Response

Get in touch with us

Reach Us

G.R. Health Aids Private LimitedB-15/3, GT Karnal Road, Industrial Area, Gujranwala Town, New Delhi-110033, Delhi, India

Rishab Chanana (Operations Manager)

View Mobile Number78% Call Response Rate

Send SMS
Send Email
Leave a Message, we will call you back!
Send your enquiry to this supplier
I agree to the terms and privacy policy

We Accept Online Payments

All Rights Reserved (Terms of Use)